Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 6,810,000 shares, a drop of 8.0% from the September 15th total of 7,400,000 shares. Based on an average daily trading volume, of 438,400 shares, the days-to-cover ratio is presently 15.5 days. Currently, 9.4% of the shares of the company are sold short.
Invivyd Stock Up 3.6 %
IVVD traded up $0.03 during midday trading on Wednesday, reaching $0.99. 243,622 shares of the company's stock were exchanged, compared to its average volume of 652,048. The firm has a market capitalization of $117.61 million, a price-to-earnings ratio of -0.52 and a beta of 0.63. Invivyd has a one year low of $0.81 and a one year high of $5.20. The business has a 50-day simple moving average of $0.99 and a two-hundred day simple moving average of $1.58.
Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.03). The firm had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.91 million. As a group, research analysts anticipate that Invivyd will post -0.6 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Invivyd by 3.9% in the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company's stock valued at $11,594,000 after acquiring an additional 97,496 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock valued at $866,000 after acquiring an additional 31,992 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock valued at $745,000 after acquiring an additional 474,301 shares during the last quarter. Duquesne Family Office LLC bought a new position in shares of Invivyd in the second quarter valued at approximately $629,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Invivyd by 21.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company's stock valued at $1,933,000 after acquiring an additional 77,603 shares during the last quarter. Institutional investors own 70.36% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Invivyd in a research note on Tuesday, September 3rd.
Get Our Latest Research Report on Invivyd
Invivyd Company Profile
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Further Reading
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.